CR8528A - Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de la inflamacion - Google Patents

Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de la inflamacion

Info

Publication number
CR8528A
CR8528A CR8528A CR8528A CR8528A CR 8528 A CR8528 A CR 8528A CR 8528 A CR8528 A CR 8528A CR 8528 A CR8528 A CR 8528A CR 8528 A CR8528 A CR 8528A
Authority
CR
Costa Rica
Prior art keywords
modulators
inflammation
treatment
furosemide
derivatives
Prior art date
Application number
CR8528A
Other languages
English (en)
Inventor
Minnich Anne
Kuntzweiler Theresa
Eishingdrelo Haifeng
Angelastro Michael
Lang Han-Jochen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of CR8528A publication Critical patent/CR8528A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se usaron celulas hospedantes que expresan HM74 para obtener moleculas de tipo furosemida con actividad agonista, que tiene la formula estructural que se muestra.
CR8528A 2004-02-20 2006-07-24 Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de la inflamacion CR8528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
CR8528A true CR8528A (es) 2007-06-08

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8528A CR8528A (es) 2004-02-20 2006-07-24 Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de la inflamacion

Country Status (24)

Country Link
US (2) US7232811B2 (es)
EP (1) EP1718292A1 (es)
JP (1) JP2007523166A (es)
KR (1) KR20060127141A (es)
CN (1) CN1921845A (es)
AR (1) AR047747A1 (es)
AU (1) AU2005216879B2 (es)
BR (1) BRPI0506792A (es)
CA (1) CA2557444A1 (es)
CR (1) CR8528A (es)
EC (1) ECSP066777A (es)
IL (1) IL177086A (es)
MA (1) MA28373A1 (es)
ME (1) MEP21108A (es)
MX (1) MXPA06008612A (es)
NO (1) NO20064237L (es)
NZ (1) NZ548830A (es)
RS (1) RS20060473A (es)
RU (1) RU2006133540A (es)
SG (1) SG164305A1 (es)
TN (1) TNSN06234A1 (es)
TW (1) TW200538109A (es)
WO (1) WO2005082350A1 (es)
ZA (1) ZA200606679B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
MX2007006695A (es) 2004-12-03 2007-08-14 Schering Corp Piperazinas sustituidas como antagonistas de cb1.
EP1968603A4 (en) * 2006-01-03 2013-01-16 Algebra Inc THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
EP2086329B1 (en) * 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) * 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
DE2206424A1 (de) * 1971-02-15 1972-08-24 Dumex Ltd As Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
JP2002508660A (ja) * 1997-06-12 2002-03-19 スミスクライン ビーチャム コーポレーション Ｈｍ７４ａ受容体
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
US7232811B2 (en) 2007-06-19
ECSP066777A (es) 2006-11-16
AU2005216879A1 (en) 2005-09-09
TNSN06234A1 (en) 2007-12-03
AR047747A1 (es) 2006-02-15
NO20064237L (no) 2006-09-19
CA2557444A1 (en) 2005-09-09
IL177086A (en) 2010-06-16
ZA200606679B (en) 2008-01-30
MA28373A1 (fr) 2006-12-01
EP1718292A1 (en) 2006-11-08
RS20060473A (sr) 2008-08-07
TW200538109A (en) 2005-12-01
US7556931B2 (en) 2009-07-07
BRPI0506792A (pt) 2007-05-22
WO2005082350A8 (en) 2005-12-08
MXPA06008612A (es) 2007-01-25
CN1921845A (zh) 2007-02-28
SG164305A1 (en) 2010-09-29
US20070213391A1 (en) 2007-09-13
JP2007523166A (ja) 2007-08-16
NZ548830A (en) 2010-03-26
AU2005216879B2 (en) 2009-12-10
MEP21108A (en) 2010-06-10
IL177086A0 (en) 2006-12-10
RU2006133540A (ru) 2008-03-27
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
WO2005082350A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CR20110309A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
CL2007003005A1 (es) Compuestos derivados de [1,6]-naftiridinona, moduladores de la actividad cinasa; composicion farmaceutica que los comprende; y su uso para tratar trastornos proliferativos, inflamatorios, autoinmune, del sistema nervioso central, entre otros.
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CR10286A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
CR8528A (es) Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de la inflamacion
GT200600248A (es) Aminopirimidinas como moduladores de quinasas
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
BR112014012138A2 (pt) uso de oleogéis, e, composição cosmética
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
PA8644701A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
CR8537A (es) Moduladores de HM74 de Oxidecahidronaftaleno
GT200600153A (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.
ECSP11011501A (es) 17 -alquil-17 -oxi-estratrienos
DOP2006000064A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidores de la inflamacion
BR112012007181A2 (pt) uso de um composto, composição, e, uso da composição.
UY29435A1 (es) Derivados de 5h-benzociclohepteno, procedimientos para su preparación y su uso como antiinflamatorios.
UY29482A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.
CL2007001850A1 (es) Compuestos derivados de purinona; composicion farmaceutica; y uso como agonistas del receptor hm74a, para tratar la dislipidemia, diabetes y obesidad entre otras.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)